Ed Dow, MD


  • 24 years as a Hematologist/Medical Oncologist
  • 20 years in clinical practical experience
  • 4 years experience physician executive.

Medical Affairs Strategy and Oversight; Management Oversight and Development of Clinical Phases 1-4 Clinical Trials; Post-FDA Approval Investigator Initiated Research (IIR); Investigator-Initiated Sponsored Research (IISR); Strategy and Content Creation for Global Key Opinion Leaders (KOLs); Product Marketing Strategies and Commercialization; Medical, Educational, and Promotional Review and Presentations; Medicare and Insurer Reimbursement Support; Research Grants; Global and Small Post Start-up Management of Oncology Therapeutic and Cancer Molecular Diagnostic Companies; and Budget Development.
Therapeutic Areas of Expertise: Lung Cancer, Genitourinary Cancers, Hematological Malignancies (myeloma and bone marrow transplantation), Thrombosis, Hemostasis, Von Willebrand disease (VWD), Bleeding Disorders, Oncology Genomic Profiling, Cancer Molecular Diagnostics, and Cardio-oncology.
Six publications, 12 abstracts, and four invited presentations.
AB, Harvard College, Cambridge, MA; MD, Tufts University Medical School, Boston, MA.
Medical Director, Global Medical Affairs/Blood Disorders, Hematology Franchise Baxalta (Shire)
Medical Affairs, oversight, product development, and global launch lead for Vonicog Alfa (approved as VONVENDI in US) for the treatment of von Willebrand disease (VWD) and recombinant replacement enzyme therapy for rare bleeding disorders. Responsible for Phase 4/Post-Approval studies, investigator-initiated research (IIR), content strategy development, publication plan, concept and synopsis review, and KOL recruitment for co-authoring.
Director, Medical Affairs, Foundation Medicine, Inc. (FMI)
Responsible for Medical Affairs Strategy and Organization. Created and led key cross-functional teams to build Medical support of Product Marketing and Commercial teams. Built, grew, and developed FMI’s External Speakers Bureau to educate and promote presentations on comprehensive genomic profiling of cancer and FMI’s services. Managed, reviewed, updated, and standardized all medical commercial/promotional presentations. Created and oversaw team of Oncology RN reviewers to generate Medicare and Insurer reimbursement support for cancer genomic profiling and testing. Reviewed and voted on research proposals and fostered KOL relationships. Managed and coordinated all scientific presentations and publications.
Associate Medical Director, Global Medical Affairs, Takeda Millennium Pharmaceuticals
Member of cross-functional team that generated two successful FDA label additions for Velcade® (bortezomib). Planned and led advisory boards with both national and regional level myeloma and lymphoma KOLs. Medical Lead for Velcade® Investigator-Initiated Studies Research (IISR) Program. Oversight of 216 active studies. Led the IRC (IISR Review Committee) in reviewing all Letters of Intent (LOI) or Summaries of Proposed Research (SOPRs) and voting on proposals and amendments. Developed relationship with NIH’s NCI / CTEP (Clinical Trials Evaluation Program). Revised and wrote internal guidance for the IISR program. Researched Initiative on Cardiovascular Safety Profile of Proteasome Inhibitor Class agents. Advised medical and patient care needs for marketing strategies, safety reviews, global reporting, and promotional and sales training materials.
Senior Staff Physician, Department of Hematology-Oncology, Attending Physician for Multi-Disciplinary Thoracic Oncology Clinic, Lahey Clinic
Solo Practitioner/ Physician Proprietor, Hematology-Oncology, Boston Hematology- Oncology, The Cancer Center of Boston
Preceptor, Instructor, Harvard Medical School
Preceptor, Internal Medicine, Physician Assistant Program, Massachusetts College of Pharmacy

Subscribe and Follow

Have the latest akta Pharmaceutical Development news delivered right to your inbox. 
And we will never share your information.